On March 2, 2019, the SEC filed an emergency action charging Arbutus Biopharma Corp. ("AB-343") with violations of the antifraud provisions of the federal securities laws.  The SEC's complaint alleges that AB-343 violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, AB-343 has been approved by the FDA as a safe, effective, and effective treatment for HBV.  The SEC's complaint, filed in the U.S. District Court for the Southern District of New York, charges AB-343 with violations of the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and seeks injunctive relief, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties.  The SEC's complaint charges AB-343 with violations of Section 10(b) of the Exchange Rules and Rule 10b-5 thereunder, seeks disgorgement of ill-gotten gains, prejudgment interest, and civil penalties.  Without admitting or denying the SEC's allegations, AB-343 has been approved by the U.S. Attorney's Office for the Southern District of New York, the Department of Justice, and the Federal Bureau of Investigation.  The SEC's continuing investigation is being conducted by Michael Sofia, David Hastings, and Thomas Yip of the Boston Regional Office.  The litigation will be led by Mr. Sofia.  The SEC appreciates the assistance of the U.S. Attorney's Office for New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors toÂ check the background of anyone selling or offering them an investment using the SEC'sÂ Investor.govÂ Investor.govÂ toÂ find out more aboutÂ AB-343 andÂ AB-343.